EFFICACY OF TYPE 2 SODIUM-GLUCOSE COTRANSPORTER INHIBITORS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AGAINST THE BACKGROUND OF INSULIN RESISTANCE
Keywords:
Non-alcoholic fatty liver disease, steatosis, Dapagliflozin, SGLT2 inhibitorsAbstract
Introduction: The development of non-alcoholic fatty liver disease NAFLD, and hence insulin resistance, then type 2 diabetes mellitus in obese patients is of great importance in the choice of treatment tactics, duration, and possible ambiguous outcomes in the progression of NAFLD. Recent evidence suggests that sodium glucose cotransporter-2 (SGLT2) inhibitors inhibit the development of non-alcoholic steatohepatitis in humans, as well as improve liver steatosis in obese patients with type 2 diabetes.
Purpose: To evaluate the effectiveness of SGLT2 inhibitors in patients with NAFLD on the background of insulin resistance
Research materials and methods: we used 10 mg of dapagliflozin for 3 months in 30 patients with non-alcoholic fatty liver disease aged 20-65 years. The diagnosis of NAFLD was established by abdominal ultrasound. All patients underwent biochemical and anthropometric studies, bio impedance measurement, abdominal ultrasound before and after treatment, as well as a comparative analysis.
Research results: The average age of patients was 44.33+8.2 years. Of the 30 patients, 18 were men and 12 were women. In a comparative analysis, we observed a significant decrease in the biochemical markers of liver damage (ALT, GGT), insulin, and the index of insulin resistance. Bioimpedance measurement indicators (total fat, visceral fat. The average body mass index significantly decreased: at admission, the average was 31.05±3.44, after treatment it decreased to 28.9±2.34 (p<0.05).
Conclusion. Our study showed the potential efficacy of an SGLT-2 inhibitor in NAFLD in patients without diabetes mellitus. The results showed a significant improvement in biochemical parameters, insulin sensitivity, lipid profile, body component composition, and weight loss during dapagliflozin therapy for NAFLD.
References
Cotter, T. G., & Rinella, M. (2020). Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology, 158(7), 1851–1864. https://doi.org/10.1053/j.gastro.2020.01.052
Mamasolievna, J. N. ANTIDIABETIC DRUGS IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW. Gospodarka i Innowacje., 2024, 48, 6-13.
Agababyan R. Irina, Djabbarova M. Nafisa. Current issues in modern treatment of nonalcoholic fatty liver disease // Journal of Biomedicine and Practice. 2024, vol. 9, issue 2, pp.44-54
Агабабян И.Р., Хохлачева Д.С., Ким Г.С., Хохлачева Н.А. Изучение компонентного состава организма на ранней стадии неалкогольной жировой болезни печени. Рецепт, 2024, том 27, № 1, 120-126. https://doi.org/10.34883/PI.2024.27.1.007
Targher, G., Tilg, H., & Byrne, C. D. (2021). Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. The lancet. Gastroenterology & hepatology, 6(7), 578–588. https://doi.org/10.1016/S2468-1253(21)00020-0
Ribeiro Dos Santos, L., & Baer Filho, R. (2020). Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. Metabolism open, 5, 100028. https://doi.org/10.1016/j.metop.2020.100028
Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017). Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Current therapeutic research, clinical and experimental, 87, 13–19. https://doi.org/10.1016/j.curtheres.2017.07.002
Gameil, M.A., Abdelgawad, M., Bahgat, M.H., Elsebaie, A.H., & Marzouk, R.E. (2020). Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. The Egyptian Journal of Internal Medicine, 32.
Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2. PMID: 30178600.
Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018). Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia, 61(10), 2155–2163. https://doi.org/10.1007/s00125-018-4702-3
Eriksson, J. W., Lundkvist, P., Jansson, P. A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G. B., Risérus, U., Lind, L., & Oscarsson, J. (2018). Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia, 61(9), 1923–1934. https://doi.org/10.1007/s00125-018-4675-2
Das, C., Tripathy, D., Swain, S., Sudhakaran, N., Uthansingh, K., Mallick, P., & Pati, G. K. (2021). Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. Cureus, 13(5), e14974. https://doi.org/10.7759/cureus.14974
